The MicroStrategy Endgame... - Rekt Mando
Speakers
Mando
— Professional Trader / Macro Analyst
Summary
Rekt Mando outlines a bearish case for MicroStrategy due to a $1.7B annual preferred dividend and looming bond maturities that create a cash flow death spiral. He shifted part of his MSTR short into ETH because Bit Mine's discount to NAV could force it to sell ETH into a market with no buyers. He remains bullish on gold, Eli Lilly as an AI alternative, and South Korean equities, while flagging a precarious Nasdaq double top and structural Solana overhang.
- MicroStrategy faces a cash flow crunch from STRK preferred dividends and putable converts that could lead to Chapter 11 if Bitcoin drops.
- ETH is now a better short than MSTR because Bit Mine (5% ETH holder) may be forced to sell ETH if its equity discount widens.
- Gold is seen as a long-term debasement play with a bottom in place and a clear path to new all-time highs above $5,000.
- Eli Lilly is positioned as an AI winner in healthcare due to regulatory moats and proprietary patient data, rotating away from crowded chip plays.
- South Korean stocks are a generational buy on extremely low valuations and corporate governance reforms.
- The Nasdaq is printing a second double top with no clear leader to drive the next leg higher, raising concerns of a broader pullback.
- Solana faces perpetual selling pressure from FTX estate vesting that caps upside and makes it an avoid.
- The broader crypto market and DAT trade are expected to slowly bleed supply as treasury companies unwind.
Ideas
MicroStrategy faces cash flow death spiral
MicroStrategy has a severe cash flow problem due to its $1.7B annual preferred dividend obligation on STRK, depleted cash reserves after buying back converts, and $6B+ of putable convertible bonds that must be repaid in 2027-2028. If Bitcoin drops to 50-35K, the Bitcoin stack would nearly match total liabilities, triggering a potential death spiral where the company must sell stock or Bitcoin. The equity MNAV has already compressed to 1.0 from 1.3, and a Chapter 11 liquidation could force Bitcoin sales near $30K. The speaker covered 85% of his short at a large profit but maintains a small short because the thesis remains intact and the end of the DAT trade is underway.
ETH forced selling by Bit Mine looming
Ethereum is a better short now than MicroStrategy. Bit Mine, the largest single ETH holder (nearly 5% of supply), has seen its equity MNAV drop from 1.0 to 0.86. If MNAV falls further to 0.7–0.75, shareholder pressure will force Bit Mine to sell ETH to buy back its own stock, unleashing massive unabsorbable supply. Tom Lee has completed his buying campaign and has no capital left. The Ethereum Foundation is cutting 40% of staff and is effectively broke, removing another large buyer. With no natural demand, ETH faces a relentless supply overhang from BIT treasury unwinds, making it an asymmetric short.
Solana: perpetual FTX vesting supply overhang
Solana has constant selling pressure from vesting FTX estate tokens that were sold in large blocks between $60 and $110. Those sales are still vesting, creating a perpetual overhang. With no major new buyer stepping in, the idea that Solana can double from current levels is unrealistic. The speaker sees this as a structural headwind that is unlikely to abate soon, making Solana unattractive.
Eli Lilly: regulatory moat and AI advantage
Eli Lilly is a standout pharma play benefiting from regulatory capture and a unique private health data moat. As AI capex narrative faces questioning from hyperscalers, capital will rotate into companies that can create real AI-enabled products. LLY’s data advantage and pharmaceutical approval pipeline make it the best-positioned company to merge AI with healthcare, while competitors like Hims lack the regulatory protection. A top analyst predicted it could become the most valuable company in the world, and the speaker has sized this trade big as an alternative AI play.
Nasdaq double top, lack of upside catalyst
The Nasdaq has printed a second double top in recent months. The previous rotation from Mag 7 to AI chip supply chain drove the index to new highs, but now those chip names are crowded and the hyperscalers are under pressure for massive AI capex commitments. There is no obvious next catalyst to take the Nasdaq from 29K to 35K—robotics is too small, SaaS is not big enough, and any capex pullback would hurt the recent leaders. This double top looks more precarious than the earlier one, warranting caution.
South Korea multigenerational buy on reforms
South Korea is a multigenerational buying opportunity due to extremely low valuations across all sectors, not just memory. The Korean government has signaled reforms in profit distribution and shareholder returns. Even after a strong run in memory stocks, the broader index trades at a lower EV than Chinese equities despite offering actual dividends and buybacks. The speaker recommends buying every dip for a 401k-like long-term hold.
